Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris
© Gurkan and Ellar; licensee BioMed Central Ltd. 2005
Received: 18 October 2005
Accepted: 07 December 2005
Published: 07 December 2005
The methylotrophic yeast Pichia pastoris is a popular heterologous expression host for the recombinant production of a variety of prokaryotic and eukaryotic proteins. The rapid emergence of P. pastoris as a robust heterologous expression host was facilitated by the ease with which it can be manipulated and propagated, which is comparable to that of Escherichia coli and Saccharomyces cerevisiae. P. pastoris offers further advantages such as the tightly-regulated alcohol oxidase promoter that is particularly suitable for heterologous expression of foreign genes. While recombinant production of bacterial toxins and their derivatives is highly desirable, attempts at their heterologous expression using the traditional E. coli expression system can be problematic due to the formation of inclusion bodies that often severely limit the final yields of biologically active products. However, recent literature now suggests that P. pastoris may be an attractive alternative host for the heterologous production of bacterial toxins, such as those from the genera Bacillus, Clostridium, and Corynebacterium, as well as their more complex derivatives. Here, we review the recombinant production of bacterial toxins and their derivatives in P. pastoris with special emphasis on their potential clinical applications. Considering that de novo design and construction of synthetic toxin genes have often been necessary to achieve optimal heterologous expression in P. pastoris, we also present general guidelines to this end based on our experience with the P. pastoris expression of the Bacillus thuringiensis Cyt2Aa1 toxin.
With the advent of modern molecular biology, recombinant expression is now routinely used for the production of proteins of sufficient purity and quantity for their functional characterization and/or use in downstream applications. For example, heterologous expression systems have facilitated the development of recombinant vaccines against the bacterial toxins that are the causative agents of human diseases such as tetanus, botulism and cholera [1–4]. Concurrently, biosynthesis of novel proteins is feasible by engineering of recombinant DNA constructs that comprise of unrelated genes, which are also often from very diverse organisms. For instance, immunotoxins are therapeutic agents that are typically composed of DNA encoding a tumour-specific antibody fragment fused to a gene coding for a highly potent bacterial toxin or its subunits .
Despite their crucial roles in vaccine development, therapeutic applications, control of crop pests and disease vectors, as well as in basic research and functional characterization, heterologous expression of bacterial genes and their novel recombinant fusions may still pose unique challenges. For instance, bacterial toxins often have deleterious effects on the host cell physiology that may limit the final yields or may even exclude the use of certain recombinant expression systems altogether. Furthermore, bacterial genes may be unsuitable for heterologous expression in certain recombinant expression hosts due to the inherent features of the prokaryotic DNA sequences such as differences in codon usage and/or high A+T-content that may contain cryptic eukaryotic polyadenylation signals. Finally, if the bacterial toxins or their derivatives are destined for clinical use, more stringent recombinant production methods are necessary to ensure utmost purity, hence in some cases further limiting the choice of heterologous expression hosts. In this manuscript, we review the use of the Pichia pastoris (P. pastoris) expression system for the recombinant production of bacterial toxins and their derivatives, with special emphasis on their potential clinical applications.
P. pastoris as a recombinant expression host
As a methylotrophic yeast, P. pastoris can use methanol as its sole carbon and energy source in the absence of a repressing carbon source [6, 7]. The first step in the metabolism of methanol is its oxidation to formaldehyde by the enzyme alcohol oxidase (AOX) using molecular oxygen. In addition to formaldehyde, this reaction also generates hydrogen peroxide. To avoid hydrogen peroxide toxicity, methanol metabolism takes place within a specialised organelle called the peroxisome that sequesters the toxic by-products away from the rest of the cell. Since AOX has a poor affinity for oxygen, P. pastoris compensates by generating large amounts of the enzyme, which can accumulate to comprise up to 30% of total cell protein (tcp) during induction with methanol . There are now a variety of vectors available that are mostly based on the powerful AOX1 promoter for the regulated overproduction of intracellular and secreted proteins in P. pastoris [9–11].
In contrast to the prokaryotic recombinant expression systems such as those based on Escherichia coli (E. coli), P. pastoris possesses eukaryotic features such as a secretory pathyway based on compartmentalized endomembranes, which is better equipped for post-translational modifications. Consequently, P. pastoris allows efficient secretory expression of complex recombinant proteins with correct intra- and inter-molecular disulphide bonds that do not require additional in vitro unfolding and refolding strategies. Furthermore, secreted expression in P. pastoris is a particularly attractive option because while it only secretes low-levels of endogenous proteins, it is capable of high-level secretion of the heterologously expressed proteins. P. pastoris can also be grown on simple, chemically-defined media, therefore secretion of the heterologous protein often becomes an effective purification step itself.
Other key features that contributed to the rapid emergence of P. pastoris as a robust recombinant expression host include: (1) the speed, ease and cost-effectiveness with which it can be manipulated and propagated compared to the other eukaryotic expression systems , (2) possession of tightly-regulated promoters, such as that of the alcohol oxidase 1 gene (AOX1), which is uniquely suited for the controlled expression of foreign genes [13, 14], (3) synthesis of N-linked glycosylation moieties that resemble the mammalian high-mannose type , and (4) a strong preference for aerobic growth, a key physiological trait that greatly facilitates culturing at high cell densities relative to the fermentative yeast, Saccharomyces cerevisiae (S. cerevisiae). Indeed, P. pastoris can be grown up to 130 g·l-1 dry cell weight on simple defined media . Generally an immediate improvement in the percentage yield of heterologous protein expression is also observed on going from shake-flask cultures to bioreactor cultures .
Heterologous expression of bacterial toxins and their derivatives in P. pastoris
Bacterial toxins and their derivatives successfully expressed in P. pastoris. The bacterial toxin and the species it is originating from are given, along with brief notes on the specifics of the reported recombinant expression strategies.
Bacterial toxin (species)
Remarks (expression culture type) [reference]
TeNT(H C ) (Clostridium tetani)
intracellular expression† of a synthetic‡ gene encoding the tetanus toxin fragment C (B) 
12 g·l-1 culture*
BoNTA(H C ) (Clostridium botulinum)
intracellular expression† of a synthetic gene‡ encoding the heavy fragment C of the botulinum neurotoxin serotype A [BoNTA(HC)] (B) [19, 22-25]
770 mg·l-1 culture
BoNTB(H C ) (Clostridium botulinum)
intracellular expression† of a synthetic gene‡ encoding the heavy fragment C of the botulinum neurotoxin serotype B [BoNTB(HC)] (B) [1, 20, 24]
390 mg·kg-1 cells
BoNTC 1 (H C ) (Clostridium botulinum)
intracellular expression† of a synthetic gene‡ encoding the heavy fragment C of the botulinum neurotoxin serotype C1 [BoNTC1(HC)] (B) 
200–500 mg·kg-1 cells
BoNTE(H C ) (Clostridium botulinum)
intracellular expression of a synthetic gene‡ encoding the heavy fragment C of the botulinum neurotoxin serotype E [BoNTE(HC)] (B) 
200–500 mg·kg-1 cells
BoNTF(H C ) (Clostridium botulinum)
intracellular expression of a synthetic gene‡ encoding the heavy fragment C of the botulinum neurotoxin serotype F [BoNTF(HC)] (B) [21, 26]
240 mg·kg-1 cells
DT (Corynebacterium diphtheriae)
secreted expression of a synthetic gene‡ encoding the truncated diphtheria toxin (DT) fused to a bivalent antibody fragment (B) [30-33]
120 mg·l-1 culture*
BSP1 and BSP2 (Bacillus sphaericus)
intracellular co-expression† of synthetic genes‡ encoding the mosquitocidal B. sphaericus polypeptides 1 and 2 (BSP1 and 2) (SF) 
Cry2 (Bacillus thuringiensis)
intracellular expression of Cry2 using the native bacterial DNA sequence (SF) 
Cyt2Aa1 (Bacillus thuringiensi s)
intracellular expression of a synthetic gene‡ encoding Cyt2Aa1 (SF) 
~1 mg·l-1 culture*
Cyt2Aa1 (Bacillus thuringiensis)
synthetic gene‡ encoding Cyt2Aa1 fused to a human scFv; secretory targeting resulted in ER-retention of the recombinant product (SF) 
10 mg·l-1 culture
Ace (Vibrio cholerae)
secreted expression of the accessory cholera enterotoxin (Ace) using the native bacterial DNA sequence (SF) 
7 mg·l-1 culture*
Cef (Vibrio cholerae)
secreted expression of Chinese hamster ovary (CHO) cell-elongating factor (Cef) using the native bacterial DNA sequence (SF) 
CTB (Vibrio cholerae)
secreted co-expression of the cholera toxin subunit B (CTB) and CTB-viral antigen fusion protein using the native bacterial DNA sequence (SF) 
LTB (Escherichia coli)
secreted expression of the heat-labile enterotoxin subunit B (LTB) using the native bacterial DNA sequence (SF) 
8 mg·l-1 culture
LTB (Escherichia coli)
intracellular expression of a LTB and a viral antigen fusion protein using the native bacterial DNA sequence (SF) 
Experience with the recombinant production of the Clostridium neurotoxin fragments in P. pastoris provides good examples for the typical problems encountered with the heterologous expression of bacterial toxins in this yeast and the subsequent high yields attainable once these problems are properly addressed. Clostridium botulinum is the causative agent of botulism, which is a severe neuroparalytic disease brought about by one of the seven antigenically distinct neurotoxin (BoNT) variants (A, B, C1, D, E, F and G) produced by this bacterium [1–3]. Similarly, Clostridium tetani produces tetanospasmin or the tetanus neurotoxin (TeNT) that causes the spastic paralysis condition associated with the tetanus disease. Both TeNT and the BoNT variants are potent exotoxins that are initially synthesized as a single polypeptide chain that typically undergoes subsequent proteolytic processing into a heterodimer of heavy and light chains bound together by a disulphide bond. In both TeNT and the BoNT variants, the carboxyl-terminal domain of the heavy chain (HC) is non-toxic and associated with binding to specific receptors present on the target nerve cells, and since it is antigenic, it has been exclusively used for vaccine development [1, 2]. Currently, a pentavalent botulinum toxoid from natural sources composed of variants A through E and a toxoid of variant F are used to immunize at-risk individuals, such as scientists and health care workers that handle BoNT or armed forces personnel that may be subject to weaponized forms of the bacterial toxin [2, 3]. However, this strategy has many shortcomings because: (1) C. botulinum produces only low-levels of the most toxin variants, (2) large-scale production is very costly and dangerous, requiring dedicated facilities in accordance with the current Good Manufacturing Practices, (3) the final products are whole toxins that are only partially homogenous, which may in turn influence immunogenicity or reactivity of the vaccine, and (4) the toxoiding process involves the use of chemicals such as formaldehyde and thimerosal that are still present in the final product formulation, hence rendering it reactogenic [2, 3]. Consequently, there is a great demand for the development of a new generation of recombinant vaccines that would alleviate many of the problems associated with the current toxoid formulations.
Recombinant tetanus neurotoxin fragment C [TeNT(HC)] was the first bacterial toxin that was successfully expressed in P. pastoris . Earlier attempts at heterologous TeNT(HC) expression in E. coli and S. cerevisiae necessitated the use of synthetic genes due to the unfavorable codon bias of the A+T-rich C. tetani DNA sequence and the presence of cryptic polyadenylation signals that led to premature mRNA transcript termination in yeast . Following a similar approach, Clare et al. used a synthetic gene with altered codon usage that had a substantially reduced A+T-content to achieve recombinant production of TeNT(HC) in P. pastoris with final yields as high as 12 g per liter of bioreactor culture . Recombinant production in P. pastoris of BoNT variants was also very successful when using synthetic genes that were optimized for heterologous expression in this yeast [1, 2, 19–26]. As in the case of TeNT(HC) , heterologous expression of BoNTA(HC), B(HC), and E(HC) in P. pastoris was also attempted by secretory targeting of the recombinant products [1, 2]. However, in both cases the recombinant proteins secreted into the culture medium were glycosylated due to the presence of fortuitous N-linked glycosylation sites in the prokaryotic primary amino acid sequences. This glycosylation rendered them immunologically inactive, hence unfit for vaccine development unless a costly in vitro deglycosylation step was carried out [1, 2, 18]. Accordingly, both TeNT(HC) and the BoNT(HC) variants are now exclusively produced by intracellular heterologous expression in P. pastoris (Table 1). For vaccine development, production in P. pastoris offers additional advantages over E. coli in avoiding the formation of inclusion bodies during heterologous expression and eliminating the potential presence of bacterial endotoxins requisite to achieve Food and Drug Administration licensure [2, 3].
P. pastoris also proved very useful in the development of vaccines for the heat-labile enterotoxin (LT) of E. coli and the cholera toxin (CT) of Vibrio cholerae, which both cause diarrhea in humans [4, 27]. Both LT and CT have a hetero-hexameric structure consisting of a toxic A subunit and five non-toxic B subunits that function in binding to the target cells. The LT subunit B (LTB) was successfully expressed in P. pastoris using the bacterial gene and efficiently secreted into culture medium in a native-like pentameric form that was biologically active and immunogenic . Fingerut et al. also reported intracellular expression in P. pastoris of a genetic fusion of LTB with a viral antigen to demonstrate the adjuvant activity of recombinant LTB produced in the methylotrophic yeast . Similarly, CT subunit B (CTB) and a genetic fusion of CBT with a viral vaccine antigen were successfully co-expressed in P. pastoris using the native bacterial CBT gene . This allowed efficient co-secretion of the recombinant CBT and CBT fusion proteins into the culture medium in a biologically active hetero-pentameric form, which could then be purified by a single-step affinity-tag based chromatography strategy. Other V. cholerae toxins also successfully expressed in P. pastoris are the accessory cholera toxin (Ace) and the Chinese hamster ovary (CHO) cell-elongating factor (Cef) [28, 29]. Despite having a key role in V. cholerae pathogenesis, the accessory cholera toxin (Ace) is produced only at low levels by it natural host, which initially hampered its further characterization . While recombinant production of Ace in E. coli was not feasible due to inherent toxicity effects to the host cells, Trucksis et al. reported subsequent success using the P. pastoris expression system, where secreted enterotoxin could be purified to homogeneity in a biological active form and at levels as high as 7 mg·l-1 culture .
Bacterial toxins have further clinical applications, such as in the development of novel therapeutic agents. These include immunotoxins (ITs) comprised of a potent bacterial toxin that is recombinantly fused to a cell-binding ligand such as an antibody fragment specific for tumor cells . Recombinant expression of ITs can be particularly challenging due to the deleterious effects of the toxin moiety on the host cell physiology and/or the presence of multiple disulphide bonds in the antibody fragment moiety that are requisite for its function. However, recent literature suggests that the P. pastoris expression system might be an attractive alternative for recombinant IT production. For example, Woo et al. reported successful fine-tuning of the P. pastoris expression system for the production of a recombinant IT based on a truncated version of the diphtheria toxin (DT) [30–32]. This strategy necessitated the construction of a synthetic gene optimized for P. pastoris expression that encoded the first 390 amino acids of the DT toxin (DT390) previously shown to be the minimum DT truncate suitable for IT production . The multi-domain DT390-based IT could be efficiently secreted by P. pastoris in a biologically active form and at yields as high as 10 mg·l-1 of shake-flask culture . Notably, P. pastoris proved to be a particularly suitable recombinant expression host in this case as it has a higher tolerance for DT toxicity compared to S. cerevisiae and other eukaryotes. While the introduction of a DT resistant mutation into the chromosomal EF-2 locus of P. pastoris did not help to further increase the final yields of biologically active IT, secreted expression levels as high as 120 mg·l-1 culture were eventually achieved using a bioreactor and empirically optimized methanol induction conditions [31–33].
We have recently reported the successful recombinant production in P. pastoris of the Cyt2Aa1 δ-endotoxin from the Bacillus thuringiensis (B. thuringiensis) subspecies kyushuensis, as well as that of a membrane-acting Cyt2Aa1-based IT [34, 35]. B. thuringiensis is a ubiquitous aerobic, gram-positive bacterium that is best known for its crystalline δ-endotoxin inclusions produced during sporulation . These δ-endotoxins are pore-forming proteins with very specific larvicidal activities for insects in the order of Lepidoptera, Coleoptera and Diptera. All active δ-endotoxins belong to either the Cry or Cyt family of toxins that share very little amino acid sequence identity but are both initially produced as protoxins that need to be solubilized at the appropriate pH prior to activation by proteolytic processing. Cyt toxins are smaller than the Cry toxins and are further distinguished from the latter by: (1) their highly specific mosquitocidal activity in vivo, (2) their broad cytolytic activity to a variety of invertebrate and vertebrate cells in vitro after solubilisation and activation by proteolytic processing, and (3) their ability to spontaneously insert into membranes containing zwitterionic phospholipids with unsaturated acyl chains [37–39]. This unique combination of features makes Cyt toxins highly suitable for the development of membrane-acting ITs, an alternative idea in the field that was initially explored in our laboratory using chemical conjugation strategies [40, 41].
Considering that recombinant production methods would provide more homogenous Cyt-based ITs compared to the chemical conjugation strategies, subsequent attempts in our laboratory were based on the use of the E. coli expression system. However, this strategy led to only limited success due to the invariable formation of inclusion bodies in this prokaryotic expression host, which in turn limited the final yields of biologically active Cyt-based ITs. Consequently, we next attempted the recombinant production of Cyt2Aa1-based ITs in P. pastoris using the native bacterial gene. However, as it has been the case for the majority of other bacterial toxins that are also encoded by A+T-rich genes (Table 1), recombinant production of Cyt2Aa1 and Cyt2Aa1-based ITs in P. pastoris necessitated de novo design and construction of a synthetic toxin gene that was optimized for heterologous expression in this yeast [34, 35]. Since de novo design and construction of synthetic genes is often a prerequisite for achieving heterologous expression of bacterial toxins in P. pastoris (Table 1), we present general guidelines to this end in the next section based on our experience with the heterologous Cyt2Aa1 expression in this yeast.
In contrast to the intracellular expression of the native bacterial gene in P. pastoris, that of the synthetic gene led to the recombinant production of the Cyt2Aa toxin, albeit severe product toxicity effects were observed . Similar toxicity effects were also observed with the intracellular expression of the Cyt2Aa1-based IT in the same heterologous expression host, which could be largely alleviated by the secretory targeting of the recombinant product. While the Cyt2Aa1-based IT failed to be secreted from the P. pastoris cells, secretory targeting proved beneficial in this case since it sequestered the deleterious recombinant product from the yeast cytosol, where a wide range of organelles would otherwise be prone to Cyt2Aa1-based membrane damage . Instead, the recombinant Cyt2Aa1-based IT accumulated to high-levels in the yeast endoplasmic reticulum, where the high local Ca2+ concentration in this organelle is expected to be inhibitory to the basic Cyt2Aa1 toxin activity [35, 42]. Furthermore, secretory targeting allowed proper formation of the disulphide bonds requisite for the function of the cell-binding domain of the recombinant Cyt2Aa1-based IT, which could then be recovered in a biologically active form at 10 mg·l-1 culture by a chaotropic denaturation step that was followed with an on-the-column refolding strategy . While the final yield of biologically active Cyt2Aa1-based IT could be potentially increased through the selection of multi-copy integrants of the recombinant expression cassette and/or large-scale bioreactor cultures (Table 1), we did not find this to be necessary for the purposes of our project, which was the development of an in vitro model system to test the potency of Cyt2Aa1-based ITs. However, it has also not escaped our attention that Cyt2Aa1-expressing P. pastoris cells can have further potential use in the control of disease vectors, as has proved to be the case for the last two examples of P. pastoris heterologous expression that we present below.
Recombinant expression in P. pastoris of the B. thuringiensis insecticidal Cry2 toxin has also been described using the native bacterial gene . In addition, high-level (up to 30% tcp) P. pastoris co-expression of two biologically active B. sphaericus mosquitocidal proteins BSP1 and BSP2 was reported using synthetic genes that were optimized for heterologous expression in this yeast . Here, P. pastoris cells expressing the B. sphaericus insecticidal proteins were heat-killed without a significant reduction in the biological activity of the recombinant toxins and then fed to Dipteran larvae, which are filter-feeders that usually find yeast cells palatable . This strategy has a minimal risk of releasing the heterologous toxin gene into environment since it would be integrated into the yeast genome unlike the autonomous plasmids used for heterologous expression in E. coli.
Design and de novo synthesis of bacterial genes for optimal expression in P. pastoris
There are now various commercial services available that offer total gene synthesis at competitive prices. However, it is also possible to design and construct any given DNA sequence using well established protocols [30, 34, 44–46]. Here we present as an example, the strategy that we have successfully used for the design and de novo construction of a synthetic gene coding for the B. thuringiensis Cyt2Aa1 toxin that was optimized for expression in P. pastoris [34, 35].
P. pastoris codon preference. This codon preference table was compiled from literature and is based on highly expressed genes in P. pastoris, as well as those in other yeast species such as S. cerevisiae [44, 51-53].
P. pastoris is a robust recombinant expression host that has also seemingly emerged as an alternative heterologous expression host for a variety of bacterial toxins and their derivatives. In particular, secretory targeting is an advantageous strategy for the recombinant production of toxins and/or their derivatives that require proteolytic processing and/or proper disulphide bond-formation for their activity. In this respect, P. pastoris may be better suited than the E. coli- and S. cerevisiae-based expression systems and it may also allow higher yields of biologically active recombinant protein as it can be grown to high cell densities under aerobic conditions. As in the case of B. thuringiensis Cyt2Aa1 toxin that is not secreted by the native host, secretory targeting of the fusion proteins may also help alleviate product toxicity effects on the P. pastoris cells. However, undesirable glycosylation of the secreted bacterial toxins may need to be addressed when using this strategy, such as by: (1) introducing silent mutations to remove cryptic glycosylation sites present in the prokaryotic primary amino acid sequence, (2) although it may be cost-prohibitive for large-scale applications, in vitro enzymatic deglycosylation can be carried out, or alternatively, (3) intracellular expression of the toxin can be attempted. A further potential problem that is often encountered during heterologous expression of the bacterial toxins in P. pastoris centers on differences in the codon bias of the A+T-rich prokaryotic toxin genes that can minimize or even preclude the recombinant production of the full-length proteins. However, there are now many examples in the literature on the successful use of de novo synthesized bacterial genes that are optimized for heterologous expression in this yeast.
List of abbreviations used
- AOX1 P. pastoris :
major alcohol oxidase gene
total cell protein
- BoNT and TeNT:
botulinum and tetanus neurotoxins, respectively
- BoNT(HC) and TeNT(HC):
the carboxyl-terminal domain of the heavy chain fragment of the botulinum and tetanus neurotoxins, respectively
- LT and CT:
the heat-labile E. coli enterotoxin and the V. cholerae toxin, respectively
- LTB and CTB:
B subunit of the heat-labile E. coli enterotoxin and the V. cholerae toxin, respectively
Chinese hamster ovary
truncated version of DT corresponding to the first 390 amino acid residues.
C.G. is currently sponsored by a Cystic Fibrosis Post-Doctoral Research Fellowship. We thank Drs Atanas V. Koulov and Paul LaPointe for a critical review of this manuscript.
- Smith LA: Development of recombinant vaccines for botulinum neurotoxin. Toxicon. 1998, 36: 1539-1548. 10.1016/S0041-0101(98)00146-9.View Article
- Byrne MP, Smith LA: Development of vaccines for prevention of botulism. Biochimie. 2000, 82: 955-966. 10.1016/S0300-9084(00)01173-1.View Article
- Smith LA, Jensen MJ, Montgomery VA, Brown DR, Ahmed SA, Smith TJ: Roads from vaccines to therapies. Mov Disord. 2004, 19 (Suppl 8): S48-52. 10.1002/mds.20009.View Article
- Harakuni T, Sugawa H, Komesu A, Tadano M, Arakawa T: Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems. Infect Immun. 2005, 73: 5654-5665. 10.1128/IAI.73.9.5654-5665.2005.View Article
- FitzGerald DJ, Kreitman R, Wilson W, Squires D, Pastan I: Recombinant immunotoxins for treating cancer. Int J Med Microbiol. 2004, 293: 577-582. 10.1078/1438-4221-00302.View Article
- Cereghino JL, Cregg JM: Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol Rev. 2000, 24: 45-66. 10.1016/S0168-6445(99)00029-7.View Article
- Macauley-Patrick S, Fazenda ML, McNeil B, Harvey LM: Heterologous protein production using the Pichia pastoris expression system. Yeast. 2005, 22: 249-270. 10.1002/yea.1208.View Article
- Couderc R, Baratti J: Oxidation of methanol by the yeast Pichia pastoris: purification and properties of alcohol oxidase. Agric Biol Chem. 1980, 44: 2279-2289.View Article
- Sears IB, O'Connor J, Rossanese OW, Glick BS: A versatile set of vectors for constitutive and regulated gene expression in Pichia pastoris. Yeast. 1998, 14: 783-790. 10.1002/(SICI)1097-0061(19980615)14:8<783::AID-YEA272>3.0.CO;2-Y.View Article
- Higgins DR, Busser K, Comiskey J, Whittier PS, Purcell TJ, Hoeffler JP: Small vectors for expression based on dominant drug resistance with direct multicopy selection. Methods Mol Biol. 1998, 103: 41-53.
- Gurkan C, Symeonides SN, Ellar DJ: High-level production in Pichia pastoris of an anti-p185HER-2 single-chain antibody fragment using an alternative secretion expression vector. Biotechnol Appl Biochem. 2004, 39: 115-122.View Article
- Cregg JM, Barringer KJ, Hessler AY, Madden KR: Pichia pastoris as a host system for transformations. Mol Cell Biol. 1985, 5: 3376-3385.View Article
- Cregg JM, Madden KR, Barringer KJ, Thill GP, Stillman CA: Functional characterization of the two alcohol oxidase genes from the yeast Pichia pastoris. Mol Cell Biol. 1989, 9: 1316-1323.View Article
- Tschopp JF, Brust PF, Cregg JM, Stillman CA, Gingeras TR: Expression of the lacZ gene from two methanol-regulated promoters in Pichia pastoris. Nucleic Acids Res. 1987, 15: 3859-3876.View Article
- Grinna LS, Tschopp JF: Size distribution and general structural features of N-linked oligosaccharides from the methylotrophic yeast, Pichia pastoris. Yeast. 1989, 5: 107-115. 10.1002/yea.320050206.View Article
- Clare J, Sreekrishna K, Romanos M: Expression of tetanus toxin fragment C. Methods Mol Biol. 1998, 103: 193-208.
- Romanos MA, Makoff AJ, Fairweather NF, Beesley KM, Slater DE, Rayment FB, Payne MM, Clare JJ: Expression of tetanus toxin fragment C in yeast: gene synthesis is required to eliminate fortuitous polyadenylation sites in AT-rich DNA. Nucleic Acids Res. 1991, 19: 1461-1467.View Article
- Clare JJ, Rayment FB, Ballantine SP, Sreekrishna K, Romanos MA: High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Biotechnology (N Y). 1991, 9: 455-460. 10.1038/nbt0591-455.View Article
- Byrne MP, Smith TJ, Montgomery VA, Smith LA: Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun. 1998, 66: 4817-4822.
- Potter KJ, Bevins MA, Vassilieva EV, Chiruvolu VR, Smith T, Smith LA, Meagher MM: Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast Pichia pastoris. Protein Expr Purif. 1998, 13: 357-365. 10.1006/prep.1998.0910.View Article
- Byrne MP, Titball RW, Holley J, Smith LA: Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. Protein Expr Purif. 2000, 18: 327-337. 10.1006/prep.2000.1200.View Article
- Potter KJ, Zhang W, Smith LA, Meagher MM: Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype A, expressed in the methylotrophic yeast Pichia pastoris. Protein Expr Purif. 2000, 19: 393-402. 10.1006/prep.2000.1256.View Article
- Zhang W, Bevins MA, Plantz BA, Smith LA, Meagher MM: Modeling Pichia pastoris growth on methanol and optimizing the production of a recombinant protein, the heavy-chain fragment C of botulinum neurotoxin, serotype A. Biotechnol Bioeng. 2000, 70: 1-8. 10.1002/1097-0290(20001005)70:1<1::AID-BIT1>3.0.CO;2-Y.View Article
- Weatherly GT, Bouvier A, Lydiard DD, Chapline J, Henderson I, Schrimsher JL, Shepard SR: Initial purification of recombinant botulinum neurotoxin fragments for pharmaceutical production using hydrophobic charge induction chromatography. J Chromatogr A. 2002, 952: 99-110. 10.1016/S0021-9673(02)00074-2.View Article
- Zhang W, Smith LA, Plantz BA, Schlegel VL, Meagher MM: Design of methanol Feed control in Pichia pastoris fermentations based upon a growth model. Biotechnol Prog. 2002, 18: 1392-1399. 10.1021/bp025516w.View Article
- Johnson SK, Zhang W, Smith LA, Hywood-Potter KJ, Todd Swanson S, Schlegel VL, Meagher MM: Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia pastoris. Protein Expr Purif. 2003, 32: 1-9. 10.1016/j.pep.2003.07.003.View Article
- Fingerut E, Gutter B, Meir R, Eliahoo D, Pitcovski J: Vaccine and adjuvant activity of recombinant subunit B of E. coli enterotoxin produced in yeast. Vaccine. 2005, 23: 4685-4696. 10.1016/j.vaccine.2005.03.050.View Article
- Trucksis M, Conn TL, Fasano A, Kaper JB: Production of Vibrio cholerae accessory cholera enterotoxin (Ace) in the yeast Pichia pastoris. Infect Immun. 1997, 65: 4984-4988.
- McCardell BA, Sathyamoorthy V, Michalski J, Lavu S, Kothary M, Livezey J, Kaper JB, Hall R: Cloning, expression and characterization of the CHO cell elongating factor (Cef) from Vibrio cholerae O1. Microb Pathog. 2002, 32: 165-172. 10.1006/mpat.2001.0492.View Article
- Woo JH, Liu YY, Mathias A, Stavrou S, Wang Z, Thompson J, Neville DM: Gene optimization is necessary to express a bivalent anti-human anti-T cell immunotoxin in Pichia pastoris. Protein Expr Purif. 2002, 25: 270-282. 10.1016/S1046-5928(02)00009-8.View Article
- Woo JH, Liu YY, Stavrou S, Neville DM: Increasing secretion of a bivalent anti-T-cell immunotoxin by Pichia pastoris. Appl Environ Microbiol. 2004, 70: 3370-3376. 10.1128/AEM.70.6.3370-3376.2004.View Article
- Woo JH, Liu YY, Neville DM: Minimization of aggregation of secreted bivalent anti-human T cell immunotoxin in Pichia pastoris bioreactor culture by optimizing culture conditions for protein secretion. J Biotechnol. 2005, (doi:10.1016/j.jbiotec.2005.1007.1004)
- Liu YY, Woo JH, Neville DM: Targeted introduction of a diphtheria toxin resistant mutation into the chromosomal EF-2 locus of Pichia pastoris and expression of immunotoxin in the EF-2 mutants. Protein Expr Purif. 2003, 30: 262-274. 10.1016/S1046-5928(03)00129-3.View Article
- Gurkan C, Ellar DJ: Expression of the Bacillus thuringiensis Cyt2Aa1 toxin in Pichia pastoris using a synthetic gene construct. Biotechnol Appl Biochem. 2003, 38: 25-33. 10.1042/BA20030017.View Article
- Gurkan C, Ellar DJ: Expression in Pichia pastoris and purification of a membrane-acting immunotoxin based on a synthetic gene coding for the Bacillus thuringiensis Cyt2Aa1 toxin. Protein Expr Purif. 2003, 29: 103-116. 10.1016/S1046-5928(03)00012-3.View Article
- Schnepf E, Crickmore N, Van Rie J, Lereclus D, Baum J, Feitelson J, Zeigler DR, Dean DH: Bacillus thuringiensis and its pesticidal crystal proteins. Microbiol Mol Biol Rev. 1998, 62: 775-806.
- Thomas WE, Ellar DJ: Bacillus thuringiensis var israelensis crystal δ-endotoxin: effects on insect and mammalian cells in vitro and in vivo. J Cell Sci. 1983, 60: 181-197.
- Thomas WE, Ellar DJ: Mechanism of action of Bacillus thuringiensis var israelensis insecticidal δ-endotoxin. FEBS Lett. 1983, 154: 362-368. 10.1016/0014-5793(83)80183-5.View Article
- Du J, Knowles BH, Li J, Ellar DJ: Biochemical characterization of Bacillus thuringiensis cytolytic toxins in association with a phospholipid bilayer. Biochem J. 1999, 338: 185-193. 10.1042/0264-6021:3380185.View Article
- Drobniewski FA: Immunotoxins up to the present day. Biosci Rep. 1989, 9: 139-156. 10.1007/BF01115993.View Article
- al-yahyaee SA, Ellar DJ: Cell targeting of a pore-forming toxin, CytA δ-endotoxin from Bacillus thuringiensis subspecies israelensis, by conjugating CytA with anti-Thy 1 monoclonal antibodies and insulin. Bioconjug Chem. 1996, 7: 451-460. 10.1021/bc960030k.View Article
- Knowles B, Blatt M, Tester M, Horsnell J, Carroll J, Menestrina G, Ellar D: A cytolytic delta-endotoxin from Bacillus thuringiensis var. israelensis forms cation-selective channels in planar lipid bilayers. FEBS Lett. 1989, 244: 259-262. 10.1016/0014-5793(89)80540-X.View Article
- Ogunjimi AA, Chandler JM, Gbenle GO, Olukoya DK, Akinrimisi EO: Heterologous expression of cry2 gene from a local strain of Bacillus thuringiensis isolated in Nigeria. Biotechnol Appl Biochem. 2002, 36: 241-246. 10.1042/BA20020053.View Article
- Sreekrishna K, Prevatt WD, Thill GP, Davis GR, Koutz P, Barr KA, Hopkins SA: Production of Bacillus entomotoxins in methylotrophic yeast. US Patent. 1998, 5,827,684,
- Prodromou C, Pearl LH: Recursive PCR: a novel technique for total gene synthesis. Protein Eng. 1992, 5: 827-829.View Article
- Withers-Martinez C, Carpenter EP, Hackett F, Ely B, Sajid M, Grainger M, Blackman MJ: PCR-based gene synthesis as an efficient approach for expression of the A+T-rich malaria genome. Protein Eng. 1999, 12: 1113-1120. 10.1093/protein/12.12.1113.View Article
- Baim SB, Sherman F: mRNA structures influencing translation in the yeast Saccharomyces cerevisiae. Mol Cell Biol. 1988, 8: 1591-1601.View Article
- Womble DD: GCG: The Wisconsin Package of sequence analysis programs. Methods Mol Biol. 2000, 132: 3-22.
- Kozak M: Initiation of translation in prokaryotes and eukaryotes. Gene. 1999, 234: 187-208. 10.1016/S0378-1119(99)00210-3.View Article
- Pearson WR, Lipman DJ: Improved tools for biological sequence comparison. Proc Natl Acad Sci USA. 1988, 85: 2444-2448.View Article
- Bennetzen JL, Hall BD: Codon selection in yeast. J Biol Chem. 1982, 257: 3026-3031.
- Ernst JF: Codon usage and gene expression. Trends Biotechnol. 1988, 6: 196-199. 10.1016/0167-7799(88)90046-7.View Article
- Ikemura T: Correlation between the abundance of yeast transfer RNAs and the occurrence of the respective codons in protein genes. Differences in synonymous codon choice patterns of yeast and Escherichia coli with reference to the abundance of isoaccepting transfer RNAs. J Mol Biol. 1982, 158: 573-597. 10.1016/0022-2836(82)90250-9.View Article
- Cigan AM, Donahue TF: Sequence and structural features associated with translational initiator regions in yeast – a review. Gene. 1987, 59: 1-18. 10.1016/0378-1119(87)90261-7.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.